Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21389532 | 0.89 | ABL1 (0.33) | ABL1RIN1TDP1GBA1GAA | |
| SCHEMBL23255225 | 0.76 | GAA (0.33) | ABL1RIN1TDP1GAAALDH1A1 | |
| SCHEMBL23731049 | 0.74 | ABL1 (0.32) | ABL1RIN1TDP1GBA1GAA | |
| SCHEMBL18466242 | 0.67 | GBA1 (0.38) | ABL1RIN1TDP1GBA1GAA | |
| SCHEMBL21389575 | 0.64 | GAA (0.41) | ABL1RIN1TDP1GBA1GAA | |
| SCHEMBL19066322 | 0.60 | RXFP1 (0.59) | TDP1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL25073969 | 0.57 | NPC1 (0.40) | ABL1RIN1TDP1GBA1GAA | |
| SCHEMBL11371116 | 0.56 | GBA1 (0.58) | ABL1RIN1TDP1GBA1GAA | |
| SCHEMBL6233301 | 0.55 | GAA (0.46) | ABL1RIN1TDP1GBA1GAA | |
| SCHEMBL11024134 | 0.55 | GAA (0.46) | ABL1RIN1TDP1GBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-18 | — | — | US | disclosed |
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | BET1, BRD4, BRD3 | ABL1 2195/4885RIN1 3084/4885TDP1 300/4885 |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | BET1, BRD4, BRD3 | ABL1 2195/4885RIN1 3084/4885TDP1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.